Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 12 of the 16 sources its claims cite were checked for support.
Abstract
BACKGROUND: Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19. METHODS: This phase 3 randomized, observer-blinded, placebo-controlled trial was conducted at 99 centers across the United States. Persons at high risk for SARS-CoV-2 infection or its complications were randomly assigned in a 1:1 ratio to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart. The primary end point was prevention of Covid-19 illness with onset at least 14 days after the second injection in participants who had not previously been infected with SARS-CoV-2. RESULTS: The trial enrolled 30,420 volunteers who were randomly assigned in a 1:1 ratio to receive either vaccine or placebo (15,210 participants in each group). More than 96% of participants received both injections, and 2.2% had evidence (serologic, virologic, or both) of SARS-CoV-2 infection at baseline. Symptomatic Covid-19 illness was confirmed in 185 participants in the placebo group (56.5 per 1000 person-years; 95% confidence interval [CI], 48.7 to 65.3) and in 11 participants in the mRNA-1273 group (3.3 per 1000 person-years; 95% CI, 1.7 to 6.0); vaccine efficacy was 94.1% (95% CI, 89.3 to 96.8%; P<0.001). Efficacy was similar across key secondary analyses, including assessment 14 days after the first dose, analyses that included participants who had evidence of SARS-CoV-2 infection at baseline, and analyses in participants 65 years of age or older. Severe Covid-19 occurred in 30 participants, with one fatality; all 30 were in the placebo group. Moderate, transient reactogenicity after vaccination occurred more frequently in the mRNA-1273 group. Serious adverse events were rare, and the incidence was similar in the two groups. CONCLUSIONS: The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease. Aside from transient local and systemic reactions, no safety concerns were identified. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.).
Overview
CoChat Summary
TL;DR
In a phase 3 U.S. trial, mRNA-1273 (100 μg given as two doses 28 days apart) prevented symptomatic Covid-19 with 94.1% efficacy and showed no safety concerns beyond transient reactogenicity. Severe Covid-19 occurred in 30 participants, all in the placebo group.
Key findings
- Among 30,420 randomized participants (15,210 per group), the primary per-protocol analysis found symptomatic Covid-19 in 11 mRNA-1273 recipients vs. 185 placebo recipients (3.3 vs. 56.5 per 1000 person-years), for vaccine efficacy of 94.1% (95% CI, 89.3 to 96.8; P<0.001).
- Severe Covid-19 occurred in 30 participants, all in the placebo group (vaccine efficacy 100%; 95% CI could not be estimated to 1.0), including one Covid-19–related death.
- Solicited local adverse events were more frequent with mRNA-1273 after dose 1 (84.2% vs. 19.8%) and dose 2 (88.6% vs. 18.8%); solicited systemic events were also more frequent after dose 1 (54.9% vs. 42.2%) and dose 2 (79.4% vs. 36.5%). Serious adverse events were similar (0.6% in both groups).
- Efficacy was similar across subgroups, including 95.6% among participants 18 to <65 years, 86.4% among those ≥65 years, and 97.5% in communities of color.
Methods
- Phase 3 randomized, observer-blinded, placebo-controlled trial conducted at 99 U.S. centers; adults at high risk for SARS-CoV-2 infection or severe Covid-19 were assigned 1:1 to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart.
- The primary end point was prevention of symptomatic Covid-19 with onset at least 14 days after the second injection in per-protocol participants who were seronegative at baseline; cases were adjudicated, and vaccine efficacy was defined as 1 minus the hazard ratio (mRNA-1273 vs. placebo) using a stratified Cox proportional hazards model.
- Safety was assessed in all participants who received at least one injection, including solicited local and systemic adverse events for 7 days after each injection, unsolicited adverse events for 28 days, and serious/medically attended events through day 759.
Limitations
- Stated: short duration of safety and efficacy follow-up (median 64 days after the second dose; 2-year follow-up planned); no identified correlate of protection; insufficient data to assess asymptomatic infection; limited cases in older adults, racial/ethnic minorities, and previously infected persons; pregnant women and children were excluded.
- Stated: the trial was not designed to evaluate single-dose efficacy; rare adverse events are hard to detect given sample size; long-term risk of enhanced respiratory disease after exposure remains unknown.
- Evident: the primary analysis reflects only short-term follow-up, so durability of protection is unknown; subgroup estimates have wide confidence intervals (e.g., ≥65 years: 86.4%, 95% CI 61.4 to 95.2).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 3 Not checked · 79 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The efficacy of mRNA-1273 is in line with that of the recently reported BNT162b2 mRNA vaccine. 16”
What the sources say
- Supportedcites [16] 16. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 Covid-19 vaccine. N Engl J Med 2020; 383: 2603-15. source
The Abstract Results report that BNT162b2 was 95% effective in preventing Covid-19, and the Discussion likewise describes 95% efficacy after two doses. The comparison with mRNA-1273 is the citing authors’ own framing; this source supplies the BNT162b2 efficacy result. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The reactogenicity associated with immunization with mRNA-1273 in this trial is similar to that in the phase 1 data reported previously. 1,4”
What the sources say
- Supportedcites [1] 1. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med 2020; 383: 1920-31. source
The Methods identify this as a phase 1 trial of mRNA-1273 that evaluated reactogenicity. The Results (Vaccine Safety; page unavailable) report its reactogenicity findings, so it supports the citation’s reference to previously reported phase 1 data. (LLM, conf=0.88)
- Supportedcites [4] 4. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020; 383: 2427-38. source
The Discussion states that the authors observed no systematic differences in reactogenicity between the older participants in this study and younger mRNA-1273 recipients reported previously. It cautions that the small groups do not permit meaningful formal statistical comparisons, but the citing sentence makes only a qualitative comparison. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the overall population, the incidence of treatment-related severe adverse events was higher in the mRNA-1273 group (71 participants [0.5%]) than in the placebo group (28 participants [0.2%]) (Tables S8 and S15).”
plainstates an associationn = 71- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Adverse events that were deemed by the trial team to be related to the vaccine or placebo were reported among 4.5% of participants in the placebo group and 8.2% in the mRNA-1273 group.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The relative incidence of these adverse events according to vaccine group was not affected by age.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
35 more claims
Create a free account to see all 88 claims and every source verdict.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [44]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently licensed vaccines have shown efficacies of up to 95% in preventing laboratory-confirmed infection over the first few months after vaccination61–63”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The two mRNA vaccines approved to date show efficacy even after only one dose, when non-NAbs and moderate T helper 1 cell responses are detectable, but almost no NAbs.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Robust CD4+ and CD8+ T cell memory is induced after COVID-19,22,39, 40, 41 and multiple COVID-19 vaccines elicit CD4+ and CD8+ T cell responses.26,42, 43, 44, 45”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [44]
Experimental — accuracy not yet measured
43 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Self-citationRNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
The COVID-19 vaccine development landscape
Thanh Le, T., Andreadakis, Z., Kumar, A., Gómez Román, R., Tollefsen, S., Saville, M., & Mayhew, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00073-5 · Cited by 1,954
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Self-citationDeveloping Covid-19 Vaccines at Pandemic Speed
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005630 · Cited by 1,557
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Self-citation
Cited by
Items 3,401–3,500 of 10,906
Zhang, H., Gao, X., Sun, Q., Dong, X., Zhu, Z., & Yang, C. (2024) · Acta Biomaterialia · doi:10.1016/j.actbio.2024.02.004 · Cited by 21
Giambra, V., Piazzolla, V., Cocomazzi, G., Squillante, M. M., Santis, E. D., Totti, B., Cavorsi, C., Giuliani, F., Serra, N., & Mangia, A. (2022) · Vaccines · doi:10.3390/vaccines10081281 · Cited by 20
Bibliometric and visual analysis of vaccination hesitancy research from 2013 to 2022
Chen, C., Yang, Q., Tian, H., Wu, J., Chen, L., Ji, Z., Zheng, D., Chen, Y., Li, Z., & Lu, H. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2226584 · Cited by 23
Elko, E. A., Nelson, G. A., Mead, H., Kelley, E., Carvalho, S. T., Sarbo, N. G., Harms, C. E., Verche, V. L., Cardoso, A. A., Ely, J. L., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111022 · Cited by 22
COVID Arm: Delayed Hypersensitivity Reactions to SARS-CoV-2 Vaccines Misdiagnosed as Cellulitis
Lindgren, A. L., Austin, A. H., & Welsh, K. M. (2021) · Journal of Primary Care & Community Health · doi:10.1177/21501327211024431 · Cited by 20
Trakarnvanich, T., Ngamvichchukorn, T., Phumisantiphong, U., Pholtawornkulchai, K., Phochanasomboon, K., & Manomaipiboon, A. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.09.067 · Cited by 21
New-Onset Acute Kidney Disease Post COVID-19 Vaccination
Li, Y., Rao, M., & Xu, G. (2022) · Vaccines · doi:10.3390/vaccines10050742 · Cited by 21
Panikkar, A., Lineburg, K. E., Raju, J., Chew, K. Y., Ambalathingal, G. R., Rehan, S., Swaminathan, S., Crooks, P., Texier, L. L., Beagley, L., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010339 · Cited by 21
Matveeva, O. V., & Ershov, A. (2022) · Vaccines · doi:10.3390/vaccines10070984 · Cited by 21
Vaccination for Respiratory Infections in Patients with Heart Failure
Girerd, N., Chapet, N., Roubille, C., Roncalli, J. G., Salvat, M., Mouquet, F., Lamblin, N., Gueffet, J.-P., Damy, T., Galinier, M., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194311 · Cited by 22
Forgacs, D., Silva‐Moraes, V., Sautto, G. A., Hanley, H. B., Gattiker, J. L., Jefferson, A. M., Kolhe, R. B., & Ross, T. M. (2022) · Vaccines · doi:10.3390/vaccines10050696 · Cited by 22
Innate immunity, inflammation activation and heat-shock protein in COVID-19 pathogenesis
Danladi, J., & Sabir, H. (2021) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2021.577632 · Cited by 27
Covid-19 vaccination and pregnancy: a systematic review of maternal and neonatal outcomes
Kontovazainitis, C.-G., Katsaras, G. Ν., Gialamprinou, D., & Mitsiakos, G. (2023) · Journal of Perinatal Medicine · doi:10.1515/jpm-2022-0463 · Cited by 29
Affeldt, P., Koehler, F. C., Brensing, K. A., Adam, V., Burian, J., Butt, L., Gies, M., Grundmann, F., Hinrichs, S., Johannis, W., et al. (2021) · Microorganisms · doi:10.3390/microorganisms10010004 · Cited by 22
Spiliopoulou, P., van Rensburg, H. J. J., Avery, L. M., Kulasingam, V., Razak, A. R. A., Bedard, P. L., Hansen, A. R., Chruscinski, A. J., Wang, B., Kulikova, M., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-022-05548-4 · Cited by 23
Butt, A. A., Talisa, V. B., Peng, Y., Shaikh, O. S., Omer, S. B., & Mayr, F. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac178 · Cited by 21
Stærke, N. B., Reekie, J., Johansen, I. S., Nielsen, H., Benfield, T., Wiese, L., Søgaard, O. S., Tolstrup, M., Iversen, K. K., Tarp, B., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-069065 · Cited by 21
Poly(2-methyl-2-oxazoline) as a polyethylene glycol alternative for lipid nanoparticle formulation
van Zyl, D. G., Mendes, L. P., Semper, R. P., Rueckert, C., & Baumhof, P. (2024) · Frontiers in Drug Delivery · doi:10.3389/fddev.2024.1383038 · Cited by 25
Català, M., Li, X., Prats, C., & Prieto‐Alhambra, D. (2021) · Scientific Reports · doi:10.1038/s41598-021-98216-0 · Cited by 20
RNA delivery with a human virus-like particle
Gutkin, A., Rosenblum, D., & Peer, D. (2021) · Nature Biotechnology · doi:10.1038/s41587-021-01124-x · Cited by 23
Nanoemulsions and nanocapsules as carriers for the development of intranasal mRNA vaccines
Borrajo, M. L., Lou, G., Anthiya, S., Lapuhs, P., Moreira, D., Tobío, A., Loza, M. I., Vidal, A., & Alonso, M. J. (2024) · Drug Delivery and Translational Research · doi:10.1007/s13346-024-01635-5 · Cited by 23
Marks, K., & Gulick, R. M. (2023) · Annals of Internal Medicine · doi:10.7326/aitc202310170 · Cited by 23
Four cases of audio-vestibular disorders related to immunisation with SARS-CoV-2 mRNA vaccines
Ekobena, P., Rothuizen, L. E., Bedussi, F., Guilcher, P., Meylan, S., Ceschi, A., Girardin, F., & Dao, K. (2022) · International Journal of Audiology · doi:10.1080/14992027.2022.2056721 · Cited by 23
Li, J., Hu, J., Jin, D., Huo, H., Chen, N., Lin, J., & Lu, X. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02919-1 · Cited by 25
Al‐Obaydi, S., Hennrikus, E. F., Mohammad, N., Lehman, E. B., Thakur, A., & Al‐Shaikhly, T. (2022) · PLoS ONE · doi:10.1371/journal.pone.0272691 · Cited by 20
mRNA-based therapies: Preclinical and clinical applications
Qureischi, M., Mohr, J., Arellano-Viera, E., Knudsen, S. E., Vohidov, F., & Garitano-Trojaola, A. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.04.007 · Cited by 23
mRNA medicine: Recent progresses in chemical modification, design, and engineering
Hou, X., Shi, J., & Xiao, Y. (2024) · Nano Research · doi:10.1007/s12274-024-6978-6 · Cited by 28
Structural stability and RNase resistance of mRNA Polyplex micelles for systemic delivery
Dirisala, A., Uchida, S., Toh, K., Li, J., Liu, X., Wen, P., Fukushima, S., & Kataoka, K. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113935 · Cited by 23
Polymer-hybrid nanosystems for antiviral applications: Current advances
Soares, D. C. F., Poletto, F. S., Eberhardt, M. J., Domingues, S. C., Sousa, F. B. D., & Tebaldi, M. L. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112249 · Cited by 22
Clinical and Molecular Relationships between COVID-19 and Feline Infectious Peritonitis (FIP)
Sweet, A., André, N. M., Stout, A. E., Licitra, B. N., & Whittaker, G. R. (2022) · Viruses · doi:10.3390/v14030481 · Cited by 21
Gralnek, I. M., Hassan, C., Ebigbo, A., Fuchs, A., Beilenhoff, U., Antonelli, G., Bisschops, R., Arvanitakis, M., Bhandari, P., Bretthauer, M., et al. (2021) · Endoscopy · doi:10.1055/a-1700-4897 · Cited by 24
Distinct Inflammatory Programs Underlie the Intramuscular Lipid Nanoparticle Response
Dowell, W. R., Dearborn, J. S., Languon, S., Miller, Z. D., Kirch, T., Paige, S., Garvin, O., Kjendal, L., Harby, E., Zuchowski, A. B., et al. (2024) · The Journal of Immunology · doi:10.1021/acsnano.4c08490 · Cited by 26
Cutaneous adverse reactions following COVID‐19 vaccinations: A systematic review and meta‐analysis
Shafie’ei, M., Jamali, M., Akbari, Z., Sarvipour, N., Ahmadzade, M., & Ahramiyanpour, N. (2022) · Journal of Cosmetic Dermatology · doi:10.1111/jocd.15261 · Cited by 19
Engineered liposomes to deliver nucleic acid mimics in Escherichia coli
Moreira, L. F., Guimarães, N., Pereira, S., Santos, R. S., Loureiro, J. A., Ferreira, R. M., Figueiredo, C., Pereira, M. D. C., & Azevedo, N. F. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.02.012 · Cited by 20
Raethke, M., van Hunsel, F. P. A. M., Luxi, N., Lieber, T., Bellitto, C., Mulder, E., Ciccimarra, F., Riefolo, F., Thurin, N. H., Roy, D., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.03.001 · Cited by 23
Florea, A., Sy, L. S., Qian, L., Ackerson, B. K., Luo, Y., Tubert, J. E., Lee, G. S., Ku, J. H., Bruxvoort, K. J., Talarico, C. A., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac785 · Cited by 20
Li, R., Li, Y., Zou, Z., Liu, Y., Li, X., Zhuang, G., Shen, M., & Zhang, L. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2021.801763 · Cited by 22
Survival and Incidence of COVID-19 After SARS-CoV-2 Vaccination in a Series of 2391 Cancer Patients
Heudel, P., Favier, B., Solodky, M.-L., Assaad, S., Chaumard, N., Trédan, O., Bachelot, T., Ray-Coquard, I. L., Russias, B., Fournier, M.-L., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2022.01.035 · Cited by 20
Cocooning against COVID‐19: The argument for vaccinating caregivers of patients with cancer
Woodfield, M. C., Pergam, S. A., & Shah, P. D. (2021) · Cancer · doi:10.1002/cncr.33598 · Cited by 20
Niederkofler, S., Parkkila, P., Aliakbarinodehi, N., Sasanian, N., Emilsson, G., Ulkoski, D., Ferreira, C. J. O., Galenkamp, N. S., Silva, B. F. B., Lundberg, D., et al. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c17052 · Cited by 26
Safety of Global SARS-CoV-2 Vaccines, a Meta-Analysis
Chen, L., Cai, X., Zhao, T., Han, B., Xie, M., Cui, J., Zhang, J., Wang, C., Liu, B., Lu, Q., et al. (2022) · Vaccines · doi:10.3390/vaccines10040596 · Cited by 21
The Effect of Cholesterol Content on the Adjuvant Activity of Nucleic-Acid-Free Lipid Nanoparticles
Anindita, J., Tanaka, H., Yamakawa, T., Sato, Y., Matsumoto, C., Ishizaki, K., Oyama, T., Suzuki, S., Ueda, K., Higashi, K., et al. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16020181 · Cited by 22
Cao, H., Yang, S., Wang, Y., Luan, N., Yin, X., Lin, K., & Liu, C. (2021) · Vaccines · doi:10.3390/vaccines9111261 · Cited by 20
(2021) · doi:10.1101/2021.12.09.21267516 · Cited by 414
Ramirez, G. A., Della‐Torre, E., Moroni, L., Yacoub, M., & Dagna, L. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-220539 · Cited by 20
Parés‐Badell, O., Martínez‐Gómez, X., Pinós, L., Borràs-Bermejo, B., Uriona, S., Otero‐Romero, S., Rodrigo‐Pendás, J. Á., Cossio‐Gil, Y., Agustí, A., Aguilera, C., et al. (2021) · Vaccines · doi:10.3390/vaccines9121463 · Cited by 22
COVID-19 vaccination effectiveness rates by week and sources of bias: a retrospective cohort study
Ostropolets, A., & Hripcsak, G. M. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-061126 · Cited by 19
Immune response to COVID-19 in older adults
Jergović, M., Coplen, C. P., Uhrlaub, J. L., & Nikolich‐Žugich, J. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.04.017 · Cited by 21
Mambelli, F., Marinho, F. V., Andrade, J. M., de Araujo, A. C. V. S. C., Abuna, R. P. F., Fabri, V. M. R., Santos, B. D. P. O., da Silva, J. S., de Magalhães, M. T. Q., Homan, E. J., et al. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2200731 · Cited by 38
Jeda, A. S., Abbassi, S., Mousavizadeh, A., Esghaie, M., Bokharaei‐Salim, F., Jeddi, F., Shafaati, M., & Abdoli, A. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108232 · Cited by 26
Conticini, E., d’Alessandro, M., Grazzini, S., Fornaro, M., Sabella, D. V. A., Lopalco, G., Giardina, F., Colafrancesco, S., Rizzo, C., Guggino, G., et al. (2022) · Internal and Emergency Medicine · doi:10.1007/s11739-022-03028-3 · Cited by 21
Synthetic RNA-based post-transcriptional expression control methods and genetic circuits
Pardi, M. L., Wu, J., Kawasaki, S., & Saito, H. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114196 · Cited by 21
What Lessons can Be Learned From the Management of the COVID-19 Pandemic?
Quinn, G. A., Connolly, R., ÓhAiseadha, C. O., Hynds, P. D., Bagus, P., Brown, R. B., Cáceres, C. F., Craig, C. E. H., Connolly, M., Domingo, J. L., et al. (2025) · International Journal of Public Health · doi:10.3389/ijph.2025.1607727 · Cited by 27
Baltas, I., Boshier, F. A. T., Williams, C. A., Bayzid, N., Cotic, M., Guerra‐Assunção, J. A., Irish, D. N., Haque, T., Hart, J., Roy, S., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab714 · Cited by 25
Kocatürk, E., Salameh, P., Saraç, E., Vera, C., Thomsen, S. F., Zuberbier, T., Ensina, L. F., Popov, T. A., van Doorn, M. B. A., Giménez‐Arnau, A. M., et al. (2023) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2023.07.019 · Cited by 25
Tober‐Lau, P., Schwarz, T., Hillus, D., Spieckermann, J., Helbig, E. T., Lippert, L. J., Thibeault, C., Koch, W., Bergfeld, L., Niemeyer, D., et al. (2021) · Emerging infectious diseases · doi:10.3201/eid2708.210887 · Cited by 20
Alam, M. S. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e13285 · Cited by 25
Immune responses related to the immunogenicity and reactogenicity of COVID-19 mRNA vaccines
Matsumura, T., Takano, T., & Takahashi, Y. (2022) · International Immunology · doi:10.1093/intimm/dxac064 · Cited by 24
Bieniasz, P. D. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab070 · Cited by 22
Li, X., Pan, Y., Yin, Q., Wang, Z., Shan, S., Zhang, L., Yu, J., Qu, Y., Sun, L., Gui, F., et al. (2022) · Cell Discovery · doi:10.1038/s41421-022-00449-4 · Cited by 20
Droplet Microfluidics for High-Resolution Virology
Jing, W., & Han, H. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.2c00615 · Cited by 22
Gao, Y., Wang, W., Yang, Y., Zhao, Q., Yang, C., Jia, X., Liu, Y., Zhou, M., Zeng, W., Huang, X., et al. (2022) · Advanced Science · doi:10.1002/advs.202204598 · Cited by 25
Nucleocapsid Specific Diagnostics for the Detection of Divergent SARS-CoV-2 Variants
Isaacs, A., Amarilla, A. A., Aguado, J., Modhiran, N., Albornoz, E. A., Baradar, A. A., McMillan, C. L. D., Choo, J. J. Y., Idris, A., Supramaniam, A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.926262 · Cited by 23
Brockman, M., Mwimanzi, F., Lapointe, H., Sang, Y., Agafitei, O., Cheung, P. K., Ennis, S., Ng, K., Basra, S., Lim, L.-Y., et al. (2021) · medRxiv · doi:10.1101/2021.09.06.21263149 · Cited by 3
Nocebo affects after COVID-19 vaccination
Sever, P. S. (2021) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2021.100273 · Cited by 19
Bogaert, B., Debisschop, A., Ehouarne, T., Eeckhoutte, H. P. V., Volder, J. D., Jacobs, A., Pottie, E., Rycke, R. M. D., Crabbé, A., Mestdagh, P., et al. (2024) · Nano Letters · doi:10.1021/acs.nanolett.3c03345 · Cited by 22
Understanding T cell aging to improve anti-viral immunity
Zhang, H., Weyand, C. M., Goronzy, J. J., & Gustafson, C. E. (2021) · Current Opinion in Virology · doi:10.1016/j.coviro.2021.09.017 · Cited by 20
Polymeric nanocarriers for therapeutic gene delivery
Zhang, J., Yang, X., Chang, Z., Zhu, W., Ma, Y., & He, H. (2025) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2025.101015 · Cited by 51
Drzeniek, N. M., Kahwaji, N., Picht, S., Dimitriou, I. M., Schlickeiser, S., Moradian, H., Geissler, S., Schmueck‐Henneresse, M., Gossen, M., & Volk, H. (2024) · Advanced Science · doi:10.1002/advs.202308447 · Cited by 18
COVID-19 vaccine acceptance, hesitancy and refusal among Iraqi Kurdish population.
Tahir, A. I., Ramadhan, D. S., Piro, S. S., Abdullah, R. Y., Taha, A. A., & Radha, R. H. (2022) · PubMed Central · Cited by 18
Tamming, L. A., Duque, D., Tran, A., Zhang, W., Pfeifle, A., Laryea, E., Wu, J., Raman, S. N. T., Gravel, C., Russell, M. S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.785349 · Cited by 22
Yaseen, A. R., Suleman, M., Qadri, A. S., Ali, A., Arshad, I., & Khan, D. M. (2023) · In Silico Pharmacology · doi:10.1007/s40203-023-00156-2 · Cited by 22
Autoimmune liver diseases and SARS-CoV-2
Sgamato, C., Rocco, A., Compare, D., Minieri, S., Marchitto, S. A., Maurea, S., & Nardone, G. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i12.1838 · Cited by 26
Chen, P., Bergman, P., Blennow, O., Hansson, L., Mielke, S., Nowak, P., Söderdahl, G., Österborg, A., Smith, C. I. E., Vesterbacka, J., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104700 · Cited by 19
Distinct SARS-CoV-2 Antibody Responses Elicited by Natural Infection and mRNA Vaccination
de Assis, R. R., Jain, A., Nakajima, R., Jasinskas, A., Kahn, S., Palma, A. M., Parker, D. M., Chau, A. H., Leung, A., Grabar, C., et al. (2021) · eScholarship (California Digital Library) · Cited by 20
Paul, É., Brown, G. W., Kalk, A., & Ridde, V. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.07.045 · Cited by 24
Nanoscience versus Viruses: The SARS‐CoV‐2 Case
Gościańska, J., Freund, R., & Wuttke, S. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202107826 · Cited by 21
Wing, S. L., Thomas, D., Balamchi, S., Ip, J., Naylor, K. L., Dixon, S. N., McArthur, E., Kwong, J. C., Perl, J. M., Atiquzzaman, M., et al. (2023) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000108 · Cited by 21
Pepperrell, T., Rodgers, F., Tandon, P., Sarsfield, K., Pugh-Jones, M., Rashid, T., & Keestra, S. (2021) · Global Health Action · doi:10.1080/16549716.2021.1892309 · Cited by 20
Acceptance of COVID‐19 vaccines in patients with chronic diseases: A cross‐sectional study
Jiang, N., Gu, P., Sun, X. L., Han, H., Liu, W., Song, N., & Jiang, X. (2022) · Journal of Clinical Nursing · doi:10.1111/jocn.16284 · Cited by 20
COVID-19 and Sarcoidosis, Readiness for Vaccination: Challenges and Opportunities
Manansala, M., Chopra, A., Baughman, R. P., Novak, R. M., Lower, E. E., Culver, D. A., Korsten, P., Drake, W. P., Judson, M. A., & Sweiss, N. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.672028 · Cited by 21
Self-citationSu, L.-J., Wang, N.-N., Luo, R.-S., Ji, Z.-H., Gu, H., Yang, C., Xu, M.-X., Zhang, J., Chen, Q., Yu, M., et al. (2026) · Nature Biomedical Engineering · doi:10.1038/s41551-026-01640-8 · Cited by 38
Circular RNA lipid nanoparticle vaccine against SARS-CoV-2
Swingle, K. L., Hamilton, A. G., Han, X., Liao, K., Safford, H. C., Thatte, A. S., Geisler, H. C., Xu, J., Saw, T. Y., Wan, Y., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2505718122 · Cited by 28
Broadly neutralizing antibodies targeting HIV: Progress and challenges
Nandagopal, P., Khan, A., & Lawson, B. R. (2023) · Clinical Immunology · doi:10.1016/j.clim.2023.109809 · Cited by 24
de Moura, I. A., Silva, A. J. D., de Macêdo, L. S., Invenção, M. D. C. V., de Sousa, M. M. G., & de Freitas, A. C. (2022) · Pathogens · doi:10.3390/pathogens11121444 · Cited by 21
Brockman, M. A., Mwimanzi, F. M., Sang, Y., Ng, K., Agafitei, O., Ennis, S., Lapointe, H. R., Young, L., Umviligihozo, G., Burns, L., et al. (2021) · medRxiv · doi:10.1101/2021.03.17.21253773 · Cited by 20
Challenges and Opportunities for COVID-19 Vaccines in Patients with Cancer
Kuderer, N. M., Hill, J. A., Carpenter, P. A., & Lyman, G. H. (2021) · Cancer Investigation · doi:10.1080/07357907.2021.1885596 · Cited by 20
Brüssow, H. (2021) · Microbial Biotechnology · doi:10.1111/1751-7915.13818 · Cited by 18
Vulpis, E., Giulimondi, F., Digiacomo, L., Zingoni, A., Safavi‐Sohi, R., Sharifi, S., Caracciolo, G., & Mahmoudi, M. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00291 · Cited by 22
Borah, P., Xiao, X., & Lee, D. K. L. (2022) · American Journal of Health Promotion · doi:10.1177/08901171221075019 · Cited by 25
Predictors of Real-World Parents’ Acceptance to Vaccinate Their Children Against the COVID-19
Galanis, P., Vraka, I. S., Siskou, O. C., Konstantakopoulou, O., Katsiroumpa, A., Moisoglou, I., & Καϊτελίδου, Δ. (2022) · Acta medica Lituanica · doi:10.15388/amed.2021.29.1.4 · Cited by 24
The effect of HIV on COVID-19 vaccine responses
Levy, I., & Rahav, G. (2023) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000790 · Cited by 23
The HLA-II immunopeptidome of SARS-CoV-2
Weingarten-Gabbay, S., Chen, D. W., Sarkizova, S., Taylor, H. B., Gentili, M., Hernandez, G. M., Pearlman, L. R., Bauer, M. R., Rice, C. M., Clauser, K. R., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113596 · Cited by 23
Approach to COVID-19 in older adults and indications for improving the outcomes
Tana, C., Moffa, L., Falasca, K., Vecchiet, J., Tana, M., Mantini, C., Ricci, F., Ticinesi, A., Meschi, T., Cipollone, F., et al. (2023) · Annals of Medicine · doi:10.1080/07853890.2023.2265298 · Cited by 27
The Effect of the COVID-19 Vaccine on Daily Cases and Deaths Based on Global Vaccine Data
Li, Z., Liu, X., Liu, M., Wu, Z., Liu, Y., Li, W., Liu, M., Wang, X., Gao, B., Luo, Y., et al. (2021) · Vaccines · doi:10.3390/vaccines9111328 · Cited by 21
Adenoviral-vectored next-generation respiratory mucosal vaccines against COVID-19
Afkhami, S., Kang, A., Jeyanathan, V., Xing, Z., & Jeyanathan, M. (2023) · Current Opinion in Virology · doi:10.1016/j.coviro.2023.101334 · Cited by 23
Metadata
- Authors
- Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., McGettigan, J., Khetan, S., Segall, N., Solis, J., Brosz, A., Fierro, C., Schwartz, H., Neuzil, K., Corey, L., Gilbert, P., Janes, H., Follmann, D., Marovich, M., Mascola, J., Polakowski, L., Ledgerwood, J., Graham, B. S., Bennett, H., Pajon, R., Knightly, C., Leav, B., Deng, W., Zhou, H., Han, S., Ivarsson, M., Miller, J., & Zaks, T.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital (L.R.B.), Boston, and Moderna, Cambridge (H.B., R.P., C.K., B.L., W.D., H.Z., S.H., M.I., J. Miller, T.Z.) — both in Massachusetts; Baylor College of Medicine (H.M.E.S.) and Centex Studies (J.S.) — both in Houston; Meridian Clinical Research, Savannah (B.E., S.K., A.B.), and Emory University (N.R.) and Atlanta Clinical Research Center (N.S.), Atlanta — all in Georgia; University of Maryland School of Medicine, Baltimore (K.K., K.N.), and National Institute of Allergy and Infectious Diseases, Bethesda (D.F., M.M., J. Mascola, L.P., J.L., B.S.G.) — both in Maryland; Saint Louis University School of Medicine, St. Louis (S.F.); University of Illinois, Chicago, Chicago (R.N.); George Washington University School of Medicine and Health Sciences, Washington, DC (D.D.); University of California, San Diego, San Diego (S.A.S.); Vanderbilt University School of Medicine, Nashville (C.B.C.); Quality of Life Medical and Research Center, Tucson, AZ (J. McGettigan); Johnson County Clin-Tr...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-02-04
- Volume
- 384
- Issue
- 5
- Pages
- 403-416
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7787219
- OpenAlex
- W3113734454
- Cited by
- 10,119
- References
- 24
- Citations by year
- 2026: 622 · 2025: 962 · 2024: 1186 · 2023: 1691 · 2022: 2854 · 2021: 2793
- FWCI
- 240.84
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (ACTG Leadership and Operations Center UM1 AI 68636, HPTN Leadership and Operations Center UM1 AI 68619, HVTN Laboratory Center UM1 AI 68618, HVTN Leadership and Operations Center UM1 AI 68614, HVTN Statistics and Data Management Center UM1 AI, IDCRC leadership group 5 UM1 AI148684-03)
- Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (Contract No. 75A50120C00034)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- mRNA-1273 vaccine, SARS-CoV-2, COVID-19 vaccines, vaccine efficacy, vaccine safety, reactogenicity, adverse events, vulnerable populations, older adults, immunocompromised patients, breakthrough infection, severe COVID-19 prevention
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, 2019-nCoV Vaccine mRNA-1273, Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Incidence, Single-Blind Method, Treatment Outcome, Young Adult, Patient Acuity, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.